BioSpace News Archive

Genixus, a pharmaceutical company focused on transforming acute and critical care medicines, is pleased to announce the execution of a contract with the 340B Prime Vendor Program, managed by Apexus LLC., for KinetiX Propofol 1% ready-to-administer (RTA) syringes, designed to simplify workflow and support effective care delivery.

Versant Diagnostics announced their agreement with PRW Laboratories, a highly-distinguished dermatopathology laboratory based in Charlottesville, Va., that provides pathology services in multiple states across the nation.

Medigene AG, an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, will participate at the BIO International Convention, taking place June 5-8, 2023 in Boston, MA.

On May 30, China Medical System Holdings Limited (“CMS” or the “Group”) announced that on 26 May 2023, the New Drug Application (NDA) of Tildrakizumab Injection under the brand name of ILUMETRI has been approved by the National Medical Products Administration of China (NMPA).

Exactech announced their first surgery in the United Arab Emirates earlier this month, which leveraged the company’s Active Intelligence® suite, using ExactechGPS® and the Equinoxe® Planning App.

Providing people with accurate and timely information to help them take their prescription medications safely and effectively is an important priority for the U.S. Food and Drug Administration.

The shareholders of Median Technologies are invited to participate at the Shareholders’ Ordinary and Extraordinary General Meeting which will be held on Tuesday June 20, 2023, at 11:00 AM CEST at PDGB, 174 avenue Victor Hugo – 75116 Paris.

Genix Pharmaceuticals Corporation (TSXV: GENX) (OTCQB: GENPF) (“GENIX” or the “Company”) is pleased to report the results of the Annual General Meeting of shareholders held on May 18, 2023 (the “AGM”).

Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) (“Defence” or the “Company”), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies

PreveCeutical Medical Inc. (the “Company” or “PreveCeutical”) (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H), is pleased to announce that PreveCeutical is furthering the progress of its patent family directed to Sol-Gel